Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Sold by Leeward Investments LLC MA

Leeward Investments LLC MA trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 97,580 shares of the medical equipment provider’s stock after selling 2,836 shares during the quarter. Leeward Investments LLC MA’s holdings in Zimmer Biomet were worth $10,307,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Stonebridge Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $25,000. Dunhill Financial LLC boosted its holdings in shares of Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 218 shares during the period. Ashton Thomas Securities LLC acquired a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $28,000. Brooklyn Investment Group acquired a new stake in shares of Zimmer Biomet in the third quarter valued at approximately $35,000. Finally, Kentucky Trust Co acquired a new stake in shares of Zimmer Biomet in the fourth quarter valued at approximately $39,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Trading Up 1.2 %

NYSE:ZBH opened at $104.89 on Friday. The stock has a fifty day moving average price of $105.86 and a two-hundred day moving average price of $107.45. The stock has a market capitalization of $20.88 billion, a price-to-earnings ratio of 23.57, a PEG ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.99 and a current ratio of 1.91. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the previous year, the business earned $2.20 earnings per share. As a group, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.92%. The ex-dividend date was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 21.57%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on ZBH shares. Raymond James decreased their price objective on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Wells Fargo & Company upped their price target on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research note on Monday, February 10th. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.